**SUMMARY**

In the last four years getting support from the CIG grant and other sources, we have got several significant achievements in the current and as well as the other projects that are running in our research unit.

**This can be summarized as follows:**

**1. Molecular Neuro-Oncology Research Unit:**

As mentioned in the first period reporting that we have established the Molecular Neuro-Oncology Research Unit within the Department of Pediatrics in Medical University of Vienna.

The unit is currently having several national and international research activities with highly prestigious research institutions from Harvard Medical School (USA), the Amsterdam Cancer Center (the Netherlands), to Hacettepe University (Turkey). Based on these collaborations, several research activities have been initiated and in part, completed. Please see publication list.

**2.** **Academic Career and Teaching Activities**

I am currently serving as “Director” of the research unit, and became a Tenured Associate Professor in May 2015 at the Medical University of Vienna. Two PhD students and 2 MD diploma students have been graduated under my supervision. We have currently two postdocs and 2 PhD and 4 diploma students. I am also involved in teaching activities at the university**.** So far, I organized five lectures (Journal Clubs and Thesis seminar) during grant period.

**3.** **Professional Memberships:** I also become an Associate member of the “American Society of Gene & Cell Therapy” and International Society for Extracellular Vesicles (ISEV). I have been also served as Chair, and/or a speaker in some of the meeting organized by these societies.

**4.** **Current Grants (Direct costs):**

**2011-2015** EU-FP7-PEOPLE-2011-CIG, Austria **Okay Saydam (PI)**

2010-2015 Melodie Stiftung

**Saydam (PI)**, ~ 900,000 USD

2010-2015 Forschungsgesellschaft for Brain Tumors

Saydam (PI), ~ 250,000 USD

2013-2016 CHILDREN'S CANCER RESEARCH INSTITUTE, CCRI-0017

Saydam (PI), ~ 350,000 USD

**2015-2017** LKW Bauers, **Saydam (PI)** 60,000 USD

**2015-2017** Scientific-Technical Agreement with Ukraine-Austria

**Saydam (PI),** 25,000 USD

Pending

1. Extracellular Vesicle/Serum-Based Tumor Biomarker Screening Studies For Glioblastomas (Saydam PI).

KLIF, FWF: ~ 500,000 USD

2. Long noncoding RNAs in medulloblastoma tumorigenesis. (Saydam PI).

ONB, ~ 250,000 USD

**5**. **Publications**

**Peer-Reviewed articles**

**1.** Senol O., Schaaij-Visse T., Pekcan E.E, Lewandrowski G., Pham T., Piersma S., Peerdeman S.,. Stroebel T., Tannous B., Saydam N., Jimenez C., and **Saydam O**. miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth *in vivo.* Oncogene. **2015** Apr 2;34(14):1790-8. **IF 8.55**

<http://www.ncbi.nlm.nih.gov.pubmedmuw.han.srv.meduniwien.ac.at/pubmed/24858044>

**2.** Erkan E.P., Ströbel T. Grant Lewandrowski G., Tannous B., Madlener S., Czech T., Saydam N. and **Saydam O.** Depletion of minichromosome maintenance protein 7 inhibits glioblastoma multiforme tumor growth *in vivo.* Oncogene. **2014** Sep 25;33(39):4778-85.

**IF 8.55**

<http://www.ncbi.nlm.nih.gov.pubmedmuw.han.srv.meduniwien.ac.at/pubmed/24166506>

**3.** Madlener S., Ströbel T., Vose S., **Saydam O**, Brendan D. Price BD, Bruce Demple B., and Saydam N. A novel link between base excision DNA repair and telomere maintenance: Ape1/Ref-1 is required for telomere protection. Proc Natl Acad Sci U S A. **2013** Oct 29;110(44):17844-9. **IF: 9.7**

<http://www.ncbi.nlm.nih.gov.pubmedmuw.han.srv.meduniwien.ac.at/pubmed/24127576>

**4.** Mizrak A., Bolukbasi MF., Ozdener GB, Brenner GJ., S, Ströbel T., Breakefield XO., and **Saydam O**. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Molecular Therapy. **2013** Jan;21(1):101-8**. IF:7.3**

<http://www.ncbi.nlm.nih.gov.pubmedmuw.han.srv.meduniwien.ac.at/pubmed/22910294>

**5.** Bolukbasi MF., Mizrak A., Ozdener GB., Madlener S., Ströbel T., Erkan EP., Breakefield XO., and **Saydam O.** miR-1289 and “zipcode”-like sequence enrich mRNAs in microvesicles. Mol Ther Nucleic Acids **2012**, 1: e10.

<http://www.ncbi.nlm.nih.gov.pubmedmuw.han.srv.meduniwien.ac.at/pubmed/23344721>

[Non-peer reviewed scientific or medical publications/materials in print or other media](http://cv.hms.harvard.edu/index.php?page=no_peerreview)

**1.** Erkan PE., and **Saydam O**. Extracellular vesicles as novel delivery tools for cancer treatment. Cancer Drug Delivery, In Press. **Invited review IF:3.5**

|  |
| --- |
| **2.** **Saydam O.,** Glauser DL, Fraefel C. **2012.** Construction and Packaging of Herpes simplexVirus/Adeno-Associated Virus (HSV/AAV) Hybrid Amplicon Vectors Cold Spring Harb Protoc. Mar 1;**2012**(3). **IF:4.63**  **3.** Mizrak A., Senol O. Ozdener G.B., and **Saydam O**. **2012.** miRNA regulation of the Wnt signaling inmeningiomas. In Tumors of The Central Nervous System Volume 7, pp 59-67 (Ed: Hayat MA). Springer.  **4.** Madlener S. and **Saydam O. 2012.** miRNA regulation of schwannomas. In Tumors of The Central Nervous System (Ed: Hayat MA). Springer.  **5.** Peerdeman S.M, **Saydam O**., Jimenez C.R. **2012.** MENINGIOMAS: CLINICAL NEEDSAND MOLECULAR INSIGHTS. In Tumors of The Central Nervous System Volumle 7, pp 39-46 (Ed: HayatMA). Springer.  **6.** Erkan EP, Breakefield XO, **Saydam O. 2011.** miRNA signature of schwannomas: possiblerole(s) of "tumor suppressor" miRNAs in benign tumors. Oncotarget. Mar;2(3):265-70. **Invited review IF:4.78** |